IART (20) SIBN (53) SGP (43) IRMD (59) ⌘ Pro Terminal →

Beta Bionics Inc. (BBNX) — RQD Stock Rating Cockpit

$16.75 -4.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.58

Beta Bionics Inc. (BBNX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $955.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BBNX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BBNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Beta Bionics Inc. (NASDAQ: BBNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $16.75 (-4.72% 1D, market cap $955.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BBNX ranks #547 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BBNX compare to IART and SIBN in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), BBNX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 55.4%, and ROIC of -22.1%. By comparison, IART (Integra LifeSciences Holdings Corporation) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $998.2M) and SIBN (SI-BONE Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -10.3%, cap $1.00B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BBNX?

▼

Per BBNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674632), Beta Bionics Inc. generated $100.3M in revenue (+53.9% YoY), -$73.2M in net income, and -$56.2M in free cash flow against $328.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $16.58 (-1.04%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BBNX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY BBNX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (28% of score)

Altman Z-Score 12.82 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 55.4% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$17.86-5.7% Next Q

Q2 (-2Q)

Grade D$16.84+21.8% Next Q

Q3 (-1Q)

Grade D$20.51-18.3% Next Q

Current

Grade D-$16.75-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BBNX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BBNX currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.08) and Max Pain ($17.59) forces dealer call-delta covering toward $34.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BBNX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BBNX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

45.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

12.82>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE33% OF RANGE

L: $9$16.75H: $33

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on BBNX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-22.1% ROIC with 55.4% gross margin and -5.88% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 12.82 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

12/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like BBNX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BBNX)

✓Walkthrough of BBNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BBNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +63.89%📐 HORIZONTAL RANGE

2026-11-02O $17.85H $17.85L $16.75C $16.75VOL 1.29M

RES: $27.09SUP: $12.09SMA50: $19.08SMA200: $14.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BBNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BBNX Butterfly Map → + Track BBNX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +53.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BBNX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BBNX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BBNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BBNX)

Health Care Rank #547 of 1016 ⚔️ IART vs BBNX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BBNX vs. IART, SIBN, SGP, IRMD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Beta Bionics Inc. (BBNX) ranks #547 by composite RQD confidence (39/100, grade D-) and #364 by equity capitalization ($955.8M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with BBNX at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BBNX ACTIVE Beta Bionics Inc.	D-	39/100	—	55.4%	-22.1%	-4.72%	$955.8M	Benchmark Subject
IART Integra LifeSciences Holdings Corporation	E	20/100	—	50.9%	-35.0%	-0.62%	$998.2M	/iart-vs-bbnx →
SIBN SI-BONE Inc.	D+	53/100	—	79.6%	-10.3%	-5.27%	$1.00B	/sibn-vs-bbnx →
SGP SpyGlass Pharma Inc.	D-	43/100	—	—	-35.0%	-0.83%	$1.09B	/sgp-vs-bbnx →
IRMD iRadimed Corporation	C-	59/100	48.8x	76.7%	37.7%	-10.57%	$1.10B	/irmd-vs-bbnx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001674632

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Beta Bionics Inc. (BBNX) reported GAAP revenue of $100.3M (+53.9% vs. FY2024 revenue of $65.1M , and +735.8% cumulative change since FY2023) , GAAP net income of -$73.2M, operating cash flow of -$50.9M, and free cash flow of -$56.2M (-8.8% YoY). On the balance sheet, BBNX closed FY2025 with $328.7M in total assets against $0 in total debt (Altman Z-Score: 12.82, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$100.3M	-$73.2M	-$50.9M	-$56.2M	$328.7M	—
FY2024 (FY)	2024-12-31	$65.1M	-$54.8M	-$48.3M	-$51.7M	$149.6M	—
FY2023 (FY)	2023-12-31	$12.0M	-$44.1M	-$32.4M	-$32.4M	—	—

3. BBNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BBNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BBNX compare to IART and SIBN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BBNX?

Where is BBNX trading relative to its 50-day, 200-day, and 52-week technical levels?

BBNX last traded at $16.75 (-4.72% on volume of 1,073,117 shares), positioning the stock -12.21% below its 50-day simple moving average ($19.08) and +13.02% above its 200-day simple moving average ($14.82). Across its 52-week range of $8.80 to $32.71, BBNX sits at the 33.2% percentile with a 14-day RSI of 45.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($14.66 to $18.84).

BBNX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell BBNX stock right now?

Beta Bionics Inc. (BBNX) currently earns a Roarable Rating of D- (Sell — SELL) with 39/100 RQD Confidence. Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.

What is BBNX's 12-month price target and RQD AI Jury consensus?

BBNX's 12-month base price target is $15.32 (range $11.95 to $34.35), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: BBNX RQD Cockpit BBNX 12M Forecast BBNX Earnings & Move BBNX Dividends & DRIP BBNX Insiders & 13F BBNX Whale Options BBNX Profit Sankey BBNX News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BBNX — Beta Bionics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:31:34Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BBNX scores 39 out of 100 with a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

Fundamental Cash Engine: 9 / 20. Per the Roarable RQD rating, ROIC is -22.1% and FCF yield is -5.88%. For a prospective investor, this means the business is not currently converting capital into positive returns or free cash flow, so any valuation case must rest on future earnings expansion rather than current cash generation.
Whale 13F Flow: 9 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The score is below midpoint, indicating limited institutional conviction in the source data.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this is the lowest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. A low score here signals weak insider-side confidence as measured by the rating model.
Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. The stock's market-level volatility is in line with the broad market, but the pillar score reflects limited alignment with the current regime.
Forensic Balance Sheet: 11 / 20. Per the Roarable RQD rating, Altman Z is 12.82, Piotroski F is 4/9, and Debt/Equity is 0.5. This is the strongest pillar, indicating a relatively stronger balance sheet position than the other pillars, though the Piotroski score sits below the midpoint.

Taken together, the rating points to a business with a comparatively sturdy balance sheet but weak operating returns, negative cash flow, and thin insider and institutional support. Upside would require a sustained turn in operating margins and cash generation; the source data does not establish that trajectory. Valuation tradeoffs are significant given the negative margins noted in the market data.

Business

Per the profile, Beta Bionics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the market data, the company reports a gross margin of 55.4%. Not available in source data for detailed product lines, customer segments, or revenue model descriptions.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$100.3M	$-71.7M	$-73.2M	N/A	$-56.2M	$31.6M	N/A
FY 2024	$65.1M	$-45.3M	$-54.8M	N/A	$-51.7M	$30.4M	N/A
FY 2023	$12.0M	$-35.9M	$-44.1M	N/A	$-32.4M	N/A	N/A

Per the SEC financials, revenue rose from $12.0M in FY 2023 to $100.3M in FY 2025, while operating losses and free cash flow outflows widened over the same span. Per the market data, operating margin and net margin are both -60%. Per the Roarable RQD rating, ROIC is -22.1%, Altman Z-Score is 12.82, and Piotroski F-Score is 4/9. Per the Roarable RQD rating, Debt/Equity is 0.5; the debt line item is Not available in source data for the reported periods.

Recent Catalysts & News Wire Analysis

Per the recent news feed:

CATALYST (GREEN): A Yahoo Finance report stating BBNX is expected to beat earnings estimates.
RISK WATCH (RED): A TradingView report on a class action following a 37% stock drop.
MARKET WIRE (YELLOW): An Investing.com report on a Chief commercial officer stock sale of $7,015.
MARKET WIRE (YELLOW): Morningstar and The Daily Tribune News reports referencing securities class action deadlines, including a November 3rd lead-plaintiff deadline.
CATALYST (GREEN): A Yahoo Finance report on Q3 results showing a loss with revenue beating estimates.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the forward earnings and cash-flow estimates, given that analyst data is absent and forward P/E is unavailable?
What is the company's debt schedule and cash runway, since the debt line item is Not available in source data?
What is the scope and merit of the securities class action referenced in the news feed?
What drove the reported revenue growth from FY 2023 to FY 2025, and is the operating-loss trajectory expected to narrow?
What is the institutional and insider holding base, given that holders data is absent?

BBNX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Beta Bionics Inc. (BBNX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BBNX Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 8h ago

Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Yahoo Finance report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 11h ago

Beta Bionics (BBNX) Faces Class Action After 37% Stock Drop

TradingView report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 14h ago

Chief commercial officer Hopman sells $7,015 of Beta Bionics stock

Investing.com report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Morningstar • 17h ago

BBNX UPCOMING DEADLINE: SueWallSt Alerts Beta Bionics, Inc. Stockholders of Securities Class Action - Contact the Firm

Morningstar report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Daily Tribune News • 20h ago

BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm

The Daily Tribune News report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 23h ago

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates

Yahoo Finance report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

BETA BIONICS, INC. (BBNX) SHAREHOLDER ALERT Bernstein

GlobeNewswire report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Beta Bionics (BBNX) Stock Looks Expensive Even After Its 43% Fall

Simply Wall St report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BBNX Bull vs. Bear Conversation Board — What's Your Call at $16.75?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BBNX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $15.47 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BBNX (D- • RQD 39/100) a Buy at $17.58?

Welcome to the BBNX (Beta Bionics Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $13.71 (-22.0%)

Spot @ $17.58

Pump the brakes on BBNX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BBNX, but look at what you are paying: current EV/EBITDA multiples with 55.4% gross margins. Unless Beta Bionics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $21.10 (+20.0%)

Spot @ $17.58

BBNX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BBNX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $17.58 (52-wk range $8.80 - $32.71), any beat on forward guidance forces shorts and underweight funds to chase.